DarioHealth amends Series B and B-1 Preferred Stock, extends conversion period, adds dividends

DarioHealth Corp.

Mandatory conversion period extended from 15 to 18 months from original issue date.
Series B and B-1 holders get 10% dividend for fifth full quarter, 25% for sixth quarter from closing.
No additional securities were issued or sold as a result of the amendment.
Amendments filed on June 25, 2024, effective upon filing with Delaware Secretary of State.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.